Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Genuine Parts Company (GPC) Price & Performance

Cassava Sciences IncTrade
Genuine Parts CompanyTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Genuine Parts Company — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Genuine Parts Company trades at $135.22 (market cap $18.55B). The key difference: Genuine Parts Company is far larger — about 388.5× Cassava Sciences Inc's market cap, and Genuine Parts Company pays a 3.16% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAGPC
Market Cap
$47.75M$18.55B
Sector
HealthConsumer Cyclical
52-Week High
$4.64$149.26
52-Week Low
$0.87$92.47
Enterprise Value
-$34.93M$24.64B
Dividend Yield
3.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Genuine Parts Company

GPC trades at $135.63, up 2.14% today, with a bullish technical signal from moving averages but a bearish oscillator reading. The stock is supported by strong Q2 2026 earnings beats, with sales growth of 6% year-over-year and an adjusted EPS of $2.15 beating estimates. However, net income margin remains thin at 0.13% for 2025, and the P/E ratio is elevated at 542.52, indicating high valuation relative to earnings. Recent news highlights institutional buying interest and reaffirmed 2026 adjusted EPS guidance of $7.50 to $8.00.

The outlook for GPC is cautiously optimistic, with analyst consensus pointing to a $148.67 price target and a 'Buy' rating from 43% of covering analysts. Key opportunities include sustained industrial segment strength and dividend consistency, while risks involve margin pressure from inflation, high debt levels, and competitive pressures in the auto parts industry. Earnings growth and cost management are critical for future stock performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Genuine Parts Company

Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.

Read more on GPC